Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New HIV Study Shows That Large Numbers Of Women And People Of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies
Data from a historic HIV study demonstrate that it is possible to recruit large numbers of women, African Americans and Latinos into U.S.-based HIV-1 treatment studies. The study, known as GRACE, is the largest study to date in treatment-experienced adult women with HIV-1 to examine gender and race differences in response to an HIV-1 therapy -- PREZISTA(R) (darunavir) coadministered with ritonavir as part of combination therapy. GRACE findings were presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa.

Cimzia(R), The Only PEGylated Anti-TNF, Recommended For Approval In The EU For Rheumatoid Arthritis
UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for Cimzia® (certolizumab pegol), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX, has been inadequate. In these patients, Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.
News of the day
Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect").
Cardiovascular

Dr. David B. Samadi Introduces New Prostate Cancer Care Center For Robotic Surgery Patients At Mount Sinai Medical Center

The Mount Sinai Medical Center has a new re center for prostate cancer treatment. Led by David B. Samadi, M.D., Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology, the new state-of-the-art facility at 625 Madison Avenue in New York City specializes in pre- and post-surgery care for patients who undergo a robotic prostatectomy at Mount Sinai"s main campus. It also provides expertise in the treatment of other urologic cancers, including bladder and kidney. A multilingual staff offers assistance with patient travel arrangements, accommodations, and translation services when required. "The care that patients receive before and after undergoing robotic surgery is as crucial to their recovery as the procedure itself," said Dr. Samadi. "At our new facility, patients are welcomed by a caring and compassionate staff that is ready to answer their questions on a variety of issues, including concerns about their continence, kegel exercises and sexual health. There"s an ample array of learning materials and brochures, and high-definition TV screens play educational tapes, presentations and DVDs. By the time I see my patients, they are at ease, well-informed and ready to take the next steps in their prostate care. Once they undergo robotic surgery at Mount Sinai"s main campus, our new facility offers them the additional care that they need on their road to recovery." Also known as Robotic Assisted Laparoscopic Prostatectomy, robotic prostatectomy is a minimally invasive type of prostate cancer surgery that utilizes a robotic surgical unit called the da Vinci system, manufactured by Intuitive Surgical. This prostate surgery is a revolutionary and advanced procedure that profoundly reduces blood loss, pain, recovery time, hospital stays, trauma to surrounding tissue and the drastically reduced side effects of other treatments such as incontinence and sexual dysfunction. "Our goal," Dr. Samadi says, "is not just survival, but to improve the patients" quality of life." One of the nation"s leading urologic oncologists, specializing in robotics and minimally invasive surgery for prostate cancer, Dr. Samadi has achieved great success treating more than 1,800 prostate cancer patients from around the world. He is one of very few urologic oncologic surgeons in the United States trained in all three primary areas of surgery -- open, laparoscopic, and robotic. Patients interested in obtaining more information about Mount Sinai"s new prostate cancer care facility and Robotic Assisted Laparoscopic Prostatectomy may call 212-241-8779 or visit, http://www.roboticoncology.com. The Mount Sinai Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009